Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine

Exclusion Criteria

• •Prior history of other malignant tumors
• •Participation in another investigational study within 4 weeks prior to treatment start
• •Major surgery within 14 days prior to treatment start
• •Radiation treatment within 28 days prior to treatment start
• •Uncontrolled cardiac atrial or ventricular arrhythmias
• •Gastrointestinal tract disease such resulting in an inability to take oral medication
• •Known to be seropositive for HIV, HBV, or HCV
• •Uncontrolled cancer pain